Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events
Open Access
- 1 August 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 114 (5) , 381-387
- https://doi.org/10.1161/circulationaha.106.634089
Abstract
Background— Current guidelines suggest measuring high-sensitivity C-reactive protein (hs-CRP) as an aid to coronary risk assessment in adults without cardiovascular disease (CVD). Whether other inflammatory biomarkers, such as fibrinogen, add further prognostic information is uncertain. Methods and Results— In a prospective study of 27 742 initially healthy middle-aged women, the associations of baseline immunoassay fibrinogen and hs-CRP measurements with incident CVD were examined over a 10-year follow-up period. Compared with women in the bottom biomarker quintile, age-adjusted hazard ratios (95% confidence intervals [CIs]) for incident CVD for quintiles 2 to 5 of fibrinogen were 1.10 (0.86 to 1.41), 1.30 (1.03 to 1.65), 1.46 (1.16 to 1.85), and 2.43 (1.95 to 3.02); for hs-CRP they were 1.48 (1.06 to 2.05), 1.70 (1.24 to 2.33), 2.20 (1.63 to 2.96), and 3.24 (2.43 to 4.31). After further adjustment for established risk factors, both biomarkers remained associated ( P for trend ≤0.001) with incident CVD (hazard ratio, 1.35; 95% CI, 1.07 to 1.71 for top fibrinogen quintile; and hazard ratio, 1.68; 95% CI, 1.22 to 2.29 for top hs-CRP quintile compared with the bottom quintiles). Further adjustment for the other biomarker resulted in hazard ratios of 1.23 and 1.56 ( P for trend=0.02 and 0.002), respectively. Although fibrinogen correlated positively with hs-CRP ( r s =0.41, P 393 mg/dL and hs-CRP >3 mg/L compared with Conclusions— In this cohort of initially healthy women, baseline levels of fibrinogen measured with a high-quality immunoassay provided additive value to hs-CRP and traditional risk factors in predicting incident CVD.Keywords
This publication has 30 references indexed in Scilit:
- Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?The American Journal of Cardiology, 2005
- Does Elevated Plasma Fibrinogen Increase the Risk of Coronary Heart Disease?Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005
- CDC/AHA Workshop on Markers of Inflammation and Cardiovascular DiseaseCirculation, 2004
- CDC/AHA Workshop on Markers of Inflammation and Cardiovascular DiseaseCirculation, 2004
- Cause-effect relation between hyperfibrinogenemia and vascular diseaseBlood, 2004
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003
- The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease — baseline findings of the PAIS projectAtherosclerosis, 2001
- The Insulin Resistance—Dyslipidemic Syndrome of Visceral Obesity: Effect on Patients' RiskObesity Research, 1998
- Fibrinogen as a Risk Factor for Stroke and Myocardial InfarctionNew England Journal of Medicine, 1984